VOR Vor Biopharma

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference.

Goldman Sachs 44th Annual Global Healthcare Conference

Fireside Chat: Monday, June 12, 2023 at 8:00am PT

Location: Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA

A live webcast and archived replay of the fireside chat will be available on the investors section of our website, linked here:

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contact:

Media & Investors

Sarah Spencer





EN
05/06/2023

Underlying

VORVor Biopharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE
Free
VOR VOR BIOPHARMA

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Sh...

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternativ...

May 8, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
05/08/25 May 8, 2025 1 EN
Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
TPH TRI POINTE HOMES INC.
NVCR NOVOCURE LTD.
GLPI GAMING AND LEISURE PROPERTIES INC.
CNK CINEMARK HOLDINGS INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
ROKU ROKU INC. CLASS A
VICI VICI PROPERTIES INC
EPRT ESSENTIAL PROPERTIES REALTY TRUST
YMAB Y-MABS THERAPEUTICS
PEAK HEALTHPEAK PROPERTIES INC.
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
FUBO FUBOTV
IMNM IMMUNOME
VOR VOR BIOPHARMA
TNGX TANGO THERAPEUTICS
NUVL INC
NUVALENT INC
04/28/25 April 28, 2025 1 EN
David Nierengarten ... (+5)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
XNCR XENCOR INC.
NVCR NOVOCURE LTD.
YMAB Y-MABS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
VOR VOR BIOPHARMA
TNGX TANGO THERAPEUTICS
NUVL INC
NUVALENT INC
04/28/25 April 28, 2025 1 EN
Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
LEN LENNAR CORPORATION CLASS A
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
DRI DARDEN RESTAURANTS INC.
EA ELECTRONIC ARTS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
ASO ACADEMY SPORTS AND OUTDOORS
FUBO FUBOTV
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
VOR VOR BIOPHARMA
STX SEAGATE TECHNOLOGY HLDGS PLC
TTD THE TRADE DESK
GLUE INC.
GFS MONTE ROSA THERAPEUTICS INC
NTST GLOBALFOUNDRIES INC
ANRO NETSTREIT CORP
BNL ALTO NEUROSCIENCE INC
BROADSTONE NET LEASE INC
03/21/25 March 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch